Aztreonam | CAS#78110-38-0 | monobactam antibiotic

MedKoo Cat#: 317305 | Name: Aztreonam

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aztreonam is a monobactam antibiotic used primarily to treat infections caused by gram-negative bacteria. Aztreonam is a monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity. Aztreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death. This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.

Chemical Structure

Aztreonam

CAS#78110-38-0 (free acid)

Theoretical Analysis

MedKoo Cat#: 317305

Name: Aztreonam

CAS#: 78110-38-0 (free acid)

Chemical Formula: C13H17N5O8S2

Exact Mass: 435.0519

Molecular Weight: 435.43

Elemental Analysis: C, 35.86; H, 3.94; N, 16.08; O, 29.39; S, 14.73

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
5g	USD 750.00	2 Weeks
10g	USD 1,150.00	2 Weeks
25g	USD 2,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

80581-86-8 (sodium) 78110-38-0 (free acid)

Synonym

Aztreonam; Az threonam; Az-threonam; Azactam; Azthreonam; Aztreonam Esteve Brand; Aztreonam Squibb Brand;Bristol Myers Squibb Brand of Aztreonam; Bristol-Myers Squibb Brand of Aztreonam;Esteve Brand of Aztreonam; Sanofi Winthrop Brand of Aztreonam; SQ 26,776; SQ-26,776; SQ26,776; Squibb Brand of Aztreonam; Urobactam

IUPAC/Chemical Name

2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid

InChi Key

WZPBZJONDBGPKJ-CAOOACKPSA-N

InChi Code

InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8+

SMILES Code

CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 435.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Caruso C, Romano A. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2015 Apr;135(4):972-6. doi: 10.1016/j.jaci.2014.10.011. Epub 2014 Nov 22. PubMed PMID: 25457154. 2: Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29. PubMed PMID: 26024868. 3: Schechter MS, Trueman D, Farquharson R, Higuchi K, Daines CL. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. Ann Am Thorac Soc. 2015 Jul;12(7):1030-8. doi: 10.1513/AnnalsATS.201312-453OC. PubMed PMID: 26053185. 4: Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep;2(9):738-49. doi: 10.1016/S2213-2600(14)70165-1. Epub 2014 Aug 18. PubMed PMID: 25154045. 5: Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013 Jul;57(7):3299-306. doi: 10.1128/AAC.01989-12. Epub 2013 May 6. PubMed PMID: 23650162; PubMed Central PMCID: PMC3697389. 6: Hutchinson D, Barclay M, Prescott WA, Brown J. Inhaled aztreonam lysine: an evidence-based review. Expert Opin Pharmacother. 2013 Oct;14(15):2115-24. doi: 10.1517/14656566.2013.831070. Epub 2013 Aug 31. Review. PubMed PMID: 23992352. 7: Hansen C, Skov M. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis. 2015 Feb;9(1):16-21. Review. PubMed PMID: 25471692. 8: Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM; AZLI Active Comparator Study Group.. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013 Mar;12(2):130-40. doi: 10.1016/j.jcf.2012.07.006. Epub 2012 Sep 15. PubMed PMID: 22985692. 9: Oguri T, Ishii Y, Shimizu-Ibuka A. Conformational Change Observed in the Active Site of Class C β-Lactamase MOX-1 upon Binding to Aztreonam. Antimicrob Agents Chemother. 2015 Aug;59(8):5069-72. doi: 10.1128/AAC.04428-14. Epub 2015 Jun 8. PubMed PMID: 26055361; PubMed Central PMCID: PMC4505233. 10: Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, Li H, Chen H, He W, Wang Q, Wang H. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58(3):1774-8. doi: 10.1128/AAC.02123-13. Epub 2013 Dec 16. PubMed PMID: 24342639; PubMed Central PMCID: PMC3957831. 11: Estep PM, Ferreira JA, Dupree LH, Aldridge PJ, Jankowski CA. Impact of an antimicrobial stewardship initiative to evaluate β-lactam allergy in patients ordered aztreonam. Am J Health Syst Pharm. 2016 Mar 1;73(5 Suppl 1):S8-13. doi: 10.2146/ajhp150440. PubMed PMID: 26896530. 12: Zeitler K, Salvas B, Stevens V, Brown J. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm. 2012 Jan 15;69(2):107-15. doi: 10.2146/ajhp100624. Review. PubMed PMID: 22215356. 13: Buonomo A, Nucera E, De Pasquale T, Pecora V, Lombardo C, Sabato V, Colagiovanni A, Rizzi A, Aruanno A, Pascolini L, Patriarca G, Schiavino D. Tolerability of aztreonam in patients with cell-mediated allergy to β-lactams. Int Arch Allergy Immunol. 2011;155(2):155-9. doi: 10.1159/000318844. Epub 2010 Dec 22. PubMed PMID: 21196760. 14: Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827. PubMed PMID: 20695801. 15: Ye Q, Ding W, Rinaldi F, Huang Y, Miller SA, Bolgar M. Structural characterization of low level degradants in aztreonam injection and an innovative approach to aid HPLC method validation. J Pharm Biomed Anal. 2016 May 30;124:358-64. doi: 10.1016/j.jpba.2016.03.017. Epub 2016 Mar 9. PubMed PMID: 26991056. 16: Pesaturo KA, Horton ER, Belliveau P. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1076-85. doi: 10.1345/aph.1Q653. Epub 2012 Jul 3. Review. PubMed PMID: 22764322. 17: Guglani L, Abdulhamid I, Ditouras J, Montejo J. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach. Ann Pharmacother. 2012 Oct;46(10):e25. doi: 10.1345/aph.1R293. Epub 2012 Sep 25. PubMed PMID: 23012384. 18: Whitaker P, Etherington C, Williams K, Conway S, Peckham D. The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients. J Cyst Fibros. 2012 Jul;11(4):353. doi: 10.1016/j.jcf.2012.01.007. Epub 2012 Feb 16. PubMed PMID: 22341263. 19: Tunkel AR, Scheld WM. Aztreonam. Infect Control Hosp Epidemiol. 1990 Sep;11(9):486-94. Review. PubMed PMID: 2230052. 20: O'Sullivan BP, Yasothan U, Kirkpatrick P. Inhaled aztreonam. Nat Rev Drug Discov. 2010 May;9(5):357-8. doi: 10.1038/nrd3170. PubMed PMID: 20431562.